Organization: Bharat Serums and Vaccines Ltd
CMD: Mr Bharat Daftary
Bioscience Revenue: Rs 565 crore
During the fiscal year 2014-15, the bioscience revenue for Bharat Serums and Vaccines (BSV) stood at Rs 565 crore, a growth of 32 percent from Rs 428 in the FY 2013-14. Founded in 1971, Mumbai-based BSV is one of the leading player in the area of biologics.
The company focus on the research, development, manufacturing and marketing of specialized biological, pharmaceutical and biotechnology products that combat disease and enhance quality of life. It has three R&D centers located in India, Germany, and USA.
The company also has a horse farm for production of equine anti-sera and anti-toxins. Its brands are marketed all over India and exported to over 45 countries across the world.
In the FY 2014-15, the company received marketing approval for the world's first monoclonal tetanus immunoglobulin, mTIG. The other key development is the successful completion of a bioequivalence study for one its fertility drugs in comparison with the innovator, bringing the firm closer to a potential worldwide approval in targeted markets.
The other major development includes receiving an EU orphan drug designation for its biopharmaceutical molecules to treat severe acute pancreatitis. The company
claims that it is possibly the first Indian company to receive this designation. The company also observed promising growth in its international market business.
In the FY 2015-16, BSV is focusing on partnering and developing some of its biopharmaceutical molecules for eventual launch in the US and Europe. It is also identifying key emerging market countries with emphasis on our biopharmaceutical portfolio and expansion of its sales and marketing efforts. The company is also eyeing expansion of the domestic market with its recently launched molecules.